Literature DB >> 21851966

Impaired glucose metabolism and type 2 diabetes are associated with hypercoagulability: potential role of central adiposity and low-grade inflammation--the Hoorn Study.

Hanneke J B H Beijers1, Isabel Ferreira, Henri M H Spronk, Bert Bravenboer, Jacqueline M Dekker, Giel Nijpels, Hugo ten Cate, Coen D A Stehouwer.   

Abstract

INTRODUCTION: Type 2 diabetes (DM2) is associated with greater risk for cardiovascular disease (CVD), which may, at least partially, be explained by prothrombotic alterations. We therefore investigated; first, the extent to which individuals with impaired glucose metabolism (IGM) and/or DM2 had greater levels of thrombin generation than those with normal glucose metabolism (NGM); and second, whether any differences were independent of other cardiovascular risk factors, such as smoking, hypertension, dyslipidaemia, (micro)albuminuria, glycemic control and (central) adiposity, and/or were potentially 'mediated' by low-grade inflammation (high-sensitivity C-reactive protein (hsCRP)).
MATERIALS AND METHODS: We studied 744 individuals from the Hoorn Study (275 NGM, 176 IGM and 293 DM2, mean age 68.6 ± 7.1 years). Thrombin generation in platelet-poor plasma was measured using the Calibrated Automated Thrombogram and three parameters were derived: lag time, peak height and endogenous thrombin potential (ETP). Data were analyzed with multiple linear regression analyses.
RESULTS: After adjustment for age, sex, prior CVD and smoking status, individuals with IGM or DM2 had a longer lag time [ß = 0.14 min (95% CI: 0.02; 0.26)], higher peak height [ß = 7.29 nM (-1.33; 15.91)] and ETP [ß = 35.65 nM*min (0.97; 70.34)] than those with NGM. These differences were attenuated to ß = 0.06 min (-0.07; 0.19), 3.82 nM (-5.46; 13.10) and 16.34 nM*min (-20.92; 53.59), respectively, when further adjusted for waist circumference and hsCRP.
CONCLUSION: Individuals with IGM or DM2 had up to 4% higher thrombin generation compared with NGM, which may be explained, to a great extent, by the greater levels of central adiposity and related low-grade inflammation characterizing these individuals.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21851966     DOI: 10.1016/j.thromres.2011.07.033

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  15 in total

1.  Thrombin Generation Measurements in Patients Scheduled for Laparoscopic Bariatric Surgery.

Authors:  Jérémie Thereaux; Fanny Mingant; Charles Roche; Hubert Galinat; Francis Couturaud; Karine Lacut
Journal:  Obes Surg       Date:  2017-08       Impact factor: 4.129

2.  Thrombin receptor PAR4 drives canonical NLRP3 inflammasome signaling in the heart.

Authors:  Anke C Fender; Sonja Kleeschulte; Svenja Stolte; Katja Leineweber; Markus Kamler; Johannes Bode; Na Li; Dobromir Dobrev
Journal:  Basic Res Cardiol       Date:  2020-01-07       Impact factor: 17.165

3.  Impact of aging on platelet reactivity in diabetic patients receiving dual antiplatelet therapy.

Authors:  Monica Verdoia; Patrizia Pergolini; Matteo Nardin; Roberta Rolla; Francesco Tonon; Elvin Kedhi; Harry Suryapranata; Alessandro Carriero; Giuseppe De Luca
Journal:  J Thromb Thrombolysis       Date:  2019-10       Impact factor: 2.300

Review 4.  Global coagulation assays in hypercoagulable states.

Authors:  Hui Yin Lim; Geoffrey Donnan; Harshal Nandurkar; Prahlad Ho
Journal:  J Thromb Thrombolysis       Date:  2022-01-08       Impact factor: 2.300

5.  Markers of thrombin generation are associated with myocardial necrosis and left ventricular impairment in patients with ST-elevation myocardial infarction.

Authors:  C H Hansen; V Ritschel; S Halvorsen; G Ø Andersen; R Bjørnerheim; J Eritsland; H Arnesen; I Seljeflot
Journal:  Thromb J       Date:  2015-09-22

Review 6.  Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk.

Authors:  Katherine Kearney; Darren Tomlinson; Kerrie Smith; Ramzi Ajjan
Journal:  Cardiovasc Diabetol       Date:  2017-03-09       Impact factor: 9.951

7.  Peripheral Arterial Disease in Type 2 Diabetes Is Associated with an Increase in Fibrinogen Levels.

Authors:  Qin-Fen Chen; Dan Cao; Ting-Ting Ye; Hui-Hui Deng; Hong Zhu
Journal:  Int J Endocrinol       Date:  2018-11-08       Impact factor: 3.257

8.  Influence of fibrinogen and C-RP on progression of peripheral arterial disease in type 2 diabetes: a preliminary report.

Authors:  Marijan Bosevski; Golubinka Bosevska; Lily Stojanovska
Journal:  Cardiovasc Diabetol       Date:  2013-02-01       Impact factor: 9.951

9.  Viscoelasticity as a measurement of clot structure in poorly controlled type 2 diabetes patients: towards a precision and personalized medicine approach.

Authors:  Etheresia Pretorius; Janette Bester
Journal:  Oncotarget       Date:  2016-08-09

10.  Lipopolysaccharide-binding protein (LBP) reverses the amyloid state of fibrin seen in plasma of type 2 diabetics with cardiovascular co-morbidities.

Authors:  Etheresia Pretorius; Sthembile Mbotwe; Douglas B Kell
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.